Alluvi, formerly LY3414901, represents a noteworthy advancement in obesity management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receiver agonist https://alluvi-healthcare750282.alltdesign.com/alluvi-a-detailed-exploration-into-the-drug-s-possibility-62109814